TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37006503
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care involving intensive supportive therapy
Study: 37007063
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SABRT) at a starting dose of 40 Gy in 5 fractions
Study: 37007572
Drug: Hyperinsulinemic normoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic normoglycemic clamp (HNC) during surgery (insulin 2 mU/kg/min followed by 20% dextrose infusion to maintain blood glucose between 4.0 and 6.0 mmol/L until end of surgery)
Study: 37007741
Drug: Phenotype-tailored lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenotype-tailored lifestyle intervention (PLI) with various approaches based on phenotype: time-restricted volumetric low-calorie diet, low-calorie diet with pre-meal protein supplementation, low-calorie diet with intensive behavioral therapy, low-calorie diet with post-workout protein supplementation and high-intensity interval training.
Study: 37007741
Drug: Standard lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lifestyle intervention (SLI) with low-calorie diet, moderate physical activity, and weekly behavioral therapy sessions.
Study: 37007743
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 (Tα1) therapy
Study: 37007788
Drug: FNC (AZVUDINE)
Normalized name: Azvudine
DrugBank: Azvudine (DB16407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNC (AZVUDINE) added to standard treatment
Study: 37007788
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to standard treatment
Study: 37008165
Drug: CTPS1 small
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTPS1 small molecule inhibitor
Study: 37008891
Drug: Chin cup
Normalized name: CHIN-UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chin cup and bonded maxillary bite block treatment
Study: 37008942
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and gonadotropin-releasing hormone analogue (GnRHa) for four years
Study: 37009114
Drug: Varenicline titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline titrated to 1 mg bid, brief behavioral counseling, and TIQ texting support
Study: 37009114
Drug: Varenicline titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline titrated to 1 mg bid
Study: 37009425
Drug: Guajava leaf
Normalized name: PSIDIUM GUAJAVA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guajava leaf treatment, specific dosage and duration not mentioned
Study: 37009425
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for COVID-19, including antiviral agents
Study: 38205656
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy
Study: 37009915
Drug: At-home serological
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home serological tests detecting antibodies against SARS-CoV-2 (nucleocapsid or spike antigen), conducted from 1 May 2021 to 31 October 2021.
Study: 37010101
Drug: Neurohormonal antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neurohormonal antagonist therapy
Study: 37010251
Drug: Goserelin implant
Normalized name: Goserelin Implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin implant
Study: 37010549
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg qd + Sorafenib 200 mg bid 5 days-on/2 days-off
Study: 37010549
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg qd + Sorafenib (standard schedule)
Study: 37010888
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) program with digital support, 9 sessions
Study: 37010988
Drug: Liposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal irinotecan (nal-IRI) administered on days 1 and 15, and veliparib on days 5-12 and 19-25 in 28-day cycles.
Study: 37011163
Drug: Shared decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared decision-making (SDM) intervention; details on dosage and duration not available.
Study: 37011163
Drug: Community participatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community participatory approaches; details on dosage and duration not available.
Study: 37011163
Drug: Multidisciplinary, inclusive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary, inclusive research team led by a Black psychologist; details on dosage and duration not available.
Study: 37011163
Drug: Intersectionality lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intersectionality lens applied; details on dosage and duration not available.
Study: 37011169
Drug: Evidence-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based intervention to prevent victimization of trans women and trans femmes; details on dosage and duration not available.
Study: 37011526
Drug: Soticlestat (≤300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat (≤300 mg/day twice daily, weight-adjusted)
Study: 37011643
Drug: DA-EPOCH-R (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH-R (six cycles every 3 weeks of intravenous dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
Study: 37011650
Drug: Belzutifan 120
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal.
Study: 37011709
Drug: Valaciclovir (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (1 g tid for 8 weeks)
Study: 37012015
Drug: Oral atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atorvastatin (40 mg daily)
Study: 37012016
Drug: 1.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg/kg ilofotase alfa
Study: 37012068
Drug: Plasma P-tau181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma P-tau181 ≤2.32 pg/mL
Study: 37012190
Drug: Internet-delivered Dialectical
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Dialectical Behavior Therapy skills training
Study: 37012306
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 240 mg orally, 1 tablet daily for 12 months (study group, n=50)
Study: 37012306
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 240 mg orally, 1 tablet daily for an additional 12 months (after initial 12 months for control group)
Study: 37012318
Drug: Front-line endocrine
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-line endocrine therapy for gBRCAm carriers
Study: 37012318
Drug: Front-line chemotherapy
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-line chemotherapy
Study: 37012461
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate tablets (test formulation)
Study: 37012461
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate tablets (reference formulation)
Study: 37012551
Drug: Lorlatinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib as a single agent in children (12 months to <18 years)
Study: 37012551
Drug: Lorlatinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib as a single agent in adults (≥18 years)
Study: 37012551
Drug: Lorlatinib in
Normalized name: Product containing lorlatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib in combination with topotecan/cyclophosphamide in children (<18 years)
Study: 37013442
Drug: Inhaled corticosteroids/long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids/long-acting beta-agonists (ICSs/LABAs)
Study: 37013442
Drug: Long-acting muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting muscarinic antagonists (LAMAs)
Study: 37013442
Drug: Neither ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither ICS nor long-acting bronchodilators
Study: 37013610
Drug: SHR7280 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7280 (100 to 1000 mg BID)
Study: 37013954
Drug: Lenalidomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (20 mg daily from days 1 to 21 of each 28-day cycle) + Rituximab (375 mg/m2 weekly, starting on cycle 1, day 1 until cycle 2, day 1) + Venetoclax (400 mg daily at maximum tolerated dose)
Study: 37014289
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) sotalol loading dose
Study: 37014289
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral (PO) loading
Study: 37014289
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) sotalol loading
Study: 37015244
Drug: Sparsentan 400
Normalized name: sparsentan 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparsentan 400 mg once daily
Study: 37016126
Drug: Oleclumab 5-40
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W)
Study: 37016126
Drug: Oleclumab 5-40
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W) with durvalumab 10 mg/kg intravenously Q2W
Study: 37016181
Drug: Monthly migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly migraine headache days
Study: 37016303
Drug: Chemotherapy (DOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (DOS regimen)
Study: 37016303
Drug: Chemotherapy (DOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (DOS regimen) after propensity score matching
Study: 37016303
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (resection and chemotherapy)
Study: 37016309
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (nonspecific laxative)
Study: 37016326
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg oral) + Misoprostol (25 µg vaginal)
Study: 37016326
Drug: Misoprostol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (25 µg vaginal) + Placebo
Study: 37016392
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) - weekly single-day courses
Study: 37016392
Drug: Sulphadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine-pyrimethamine (SP) - monthly single-day courses
Study: 37016394
Drug: MOUD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOUD with adjunctive use of OptiMAT (MOUD+OptiMAT)
Study: 37016469
Drug: Longest daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longest daily sustained walking bout at 1-19 steps
Study: 37016906
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg oral daily and bevacizumab 15 mg/kg intravenously on day 1, repeated every 21 days until disease progression, intolerable toxicity, or death
Study: 37017254
Drug: Belimumab plus
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab plus standard therapy (ST)
Study: 37017254
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST) alone
Study: 37018064
Drug: Vorinostat (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (oral administration)
Study: 37018188
Drug: Tapering doses
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering doses of prednisone
Study: 37018188
Drug: Cumulative glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative glucocorticoid doses
Study: 37018234
Drug: Busulfan treatment
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan treatment in lymphoblastoid cell lines (LCLs)
Study: 37018234
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of expression experiment and WES data analysis
Study: 37018415
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor (CAR)-T cells enriched in memory T cells
Study: 37018468
Drug: RSVpreF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF vaccine (120 μg)
Study: 37018474
Drug: Bivalent RSV
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent RSV prefusion F protein-based vaccine (120 μg, single intramuscular injection)
Study: 37018649
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and folinic acid maintenance therapy with panitumumab
Study: 37018649
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and folinic acid maintenance therapy without panitumumab
Study: 37018790
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for 14 days
Study: 37019077
Drug: ARB dose
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB dose >0%-25%
Study: 37019077
Drug: ARB dose
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB dose >25%
Study: 37019077
Drug: ARB dose
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB dose ≤25%
Study: 37019334
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose erythropoietin (Epo)
Study: 37019367
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and Ipilimumab with Definitive Radiation Therapy
Study: 37019443
Drug: 1 g IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g IV tranexamic acid (TXA)
Study: 37019443
Drug: 1 g IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g IM tranexamic acid (TXA)
Study: 37019443
Drug: 4 g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g oral tranexamic acid (TXA)
Study: 37019619
Drug: Anti-PD-L1 therapy
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti-PD-L1 therapy
Study: 37019821
Drug: RhoA/Rho-kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhoA/Rho-kinase inhibitor (fasudil)
Study: 37020805
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) supplementation at 500 mg/day
Study: 37020837
Drug: Physiological assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological assessments of pulmonary function including spirometry, bronchodilator reversibility, static lung volumes
Study: 37020840
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg d-cycloserine
Study: 37021170
Drug: Standardized educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized educational talk (SET) on intravenous thrombolysis (IVT)
Study: 37021342
Drug: Rise of
Normalized name: TITANIUM DIOXIDE 20 mg in 1 g TOPICAL STICK [Flormar Delicious Lip Stylo Sunscreen Broad Spectrum SPF 15 DS14 Rise of Modern City]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rise of >5 bpm in weekly average NHR
Study: 37021397
Drug: Alemtuzumab administered
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab administered intravenously (IV)
Study: 37021397
Drug: Alemtuzumab administered
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab administered subcutaneously (SC)
Study: 37021546
Drug: Polyethylene glycol-coated
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-coated haemostatic patch (patch group)
Study: 37021629
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL 0.9% saline and oral simulation capsule)
Study: 37021692
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of treatment
Study: 37022502
Drug: Cognitive Restructuration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Restructuration Treatment Group (CRTG, n=13)
Study: 37022702
Drug: Metastasis-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastasis-directed therapy (MDT) with intermittent hormone therapy (combined therapy arm; n=43)
Study: 37022702
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy only (n=44)
Study: 37022706
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (3 mg/kg IV every 2 weeks plus 1 mg/kg IV every 6 weeks)
Study: 37022717
Drug: Cyclosporine solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine solution, 0.1%, applied twice daily for 29 days
Study: 37022717
Drug: Vehicle, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle, applied twice daily for 29 days
Study: 37022717
Drug: Cyclosporine solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine solution, 0.1%
Study: 37022774
Drug: Atellica® IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atellica® IM High-Sensitivity Troponin I (hs-cTnI) assay with a threshold of <10 ng/L
Study: 37023284
Drug: Higher proportions
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher proportions of network members engaging in heavy alcohol use, regular cannabis use, or other drug use
Study: 37023374
Drug: Peritumoral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral injection of 0.5% lidocaine, 7-10 minutes before surgery
Study: 37023398
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and Alternative Medicine
Study: 37023451
Drug: Levonorgestrel 52-mg
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel 52-mg Intrauterine Device
Study: 37023455
Drug: Levonorgestrel 52-mg
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel 52-mg intrauterine device (IUD)
Study: 37023659
Drug: Monthly cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly cash payment of 300 Rand conditional on school enrollment of index young women
Study: 37023705
Drug: Ipatasertib 300
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 300 mg daily, carboplatin AUC2, paclitaxel 80 mg m-2 days 1, 8, and 15 every 28 days (Arm A)
Study: 37023705
Drug: Ipatasertib 400
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 400 mg daily, carboplatin AUC2 days 1, 8, and 15 every 28 days (Arm B)
Study: 37023705
Drug: Ipatasertib 300
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 300 mg 21 days on 7 days off, capecitabine 750 mg m-2, twice a day, 7 days on 7 days off, atezolizumab 840 mg days 1 and 15 every 28 days (Arm C)
Study: 37023789
Drug: Mandatory split-dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory split-dose bowel preparation (SDBP)
Study: 37023789
Drug: Optional split-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional split-dose bowel preparation (SDBP)
Study: 37023987
Drug: Stereotactic Ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Ablative Radiotherapy in combination with Durvalumab
Study: 37024249
Drug: RMC-035 (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-035 (1.3 or 0.65 mg/kg intravenous infusion, five doses based on presurgery estimated glomerular filtration rate)
Study: 37024420
Drug: D-VMP (Daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-VMP (Daratumumab + Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Study: 37024420
Drug: VMP (Bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMP (Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Study: 37024478
Drug: Intravitreal anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Study: 37024478
Drug: Delayed or
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed or missed intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Study: 37024520
Drug: WVT078 (anti-BCMA×
Approvals — FDA: no, EMA: no, PMDA: no
Description: WVT078 (anti-BCMA× anti-CD3 bispecific antibody) administered intravenously once weekly at doses of 48-250 µg/kg (n=26)
Study: 37024520
Drug: WVT078 (anti-BCMA×
Approvals — FDA: no, EMA: no, PMDA: no
Description: WVT078 (anti-BCMA× anti-CD3 bispecific antibody)
Study: 37024811
Drug: Potential proof-of-concept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential proof-of-concept for adoptive T cell therapy against CMV and VZV